nach oben

Endocrine

Erschienen in:

01.02.2020 | Viewpoint

Growth hormone releasing hormone in the unfolded protein response context

verfasst von: Nektarios Barabutis

Erschienen in: Endocrine | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

The effects of Growth Hormone Releasing Hormone in human pathophysiology are not limited to those mediated by the Growth Hormone Releasing Hormone–Growth Hormone–Insulin-like Growth Factor-I axis. Receptors specific for this neuropeptide are expressed in a diverse variety of human tissues, to initiate multifarious signaling cascades, regulators of cellular homeostasis and survival. The Unfolded Protein Response is in charge of adaptive responses towards a plethora of challenges, able to trigger cellular repair or death. The possible involvement of Growth Hormone Releasing Hormone and its agonistic and antagonistic analogs in those events, may deliver exciting possibilities in the treatment of human disease, including the Acute Respiratory Distress Syndrome.

A.V. Schally, S. Sawano, A. Arimura, J.F. Barrett, I. Wakabayashi, C.Y. Bowers, Isolation of growth hormone-releasing hormone(GRH) from porcine hypothalami. Endocrinology 84(6), 1493–1506 (1969). https://doi.org/10.1210/endo-84-6-1493 CrossRefPubMed

K.E. Mayo, Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone. Mol. Endocrinol. 6(10), 1734–1744 (1992). https://doi.org/10.1210/mend.6.10.1333056 CrossRefPubMed

S.G. Roh, M. Doconto, D.D. Feng, C. Chen, Differential regulation of GHRH-receptor and GHS-receptor expression by long-term in vitro treatment of ovine pituitary cells with GHRP-2 and GHRH. Endocrine 30(1), 55–62 (2006). https://doi.org/10.1385/ENDO:30:1:55 CrossRefPubMed

B.D. Gaylinn, Molecular and cell biology of the growth hormone-releasing hormone receptor. Growth Horm. IGF Res. 9(Suppl A), 37–44 (1999). https://doi.org/10.1016/s1096-6374(99)80008-2 CrossRefPubMed

A. Havt, A.V. Schally, G. Halmos, J.L. Varga, G.L. Toller, J.E. Horvath, K. Szepeshazi, F. Koster, K. Kovitz, K. Groot, M. Zarandi, C.A. Kanashiro, The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc. Natl Acad. Sci. USA 102(48), 17424–17429 (2005). https://doi.org/10.1073/pnas.0506844102 CrossRefPubMed

Z. Rekasi, T. Czompoly, A.V. Schally, G. Halmos, Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc. Natl Acad. Sci. USA 97(19), 10561–10566 (2000). https://doi.org/10.1073/pnas.180313297 CrossRefPubMed

H. Kiaris, I. Chatzistamou, A.V. Schally, G. Halmos, J.L. Varga, H. Koutselini, A. Kalofoutis, Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor. Proc. Natl Acad. Sci. USA 100(16), 9512–9517 (2003). https://doi.org/10.1073/pnas.1533185100 CrossRefPubMed

N. Barabutis, E. Tsellou, A.V. Schally, S. Kouloheri, A. Kalofoutis, H. Kiaris, Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor. Proc. Natl Acad. Sci. USA 104(13), 5575–5579 (2007). https://doi.org/10.1073/pnas.0700407104 CrossRefPubMed

A.V. Schally, X. Zhang, R. Cai, J.M. Hare, R. Granata, M. Bartoli, Actions and potential therapeutic applications of growth hormone-releasing hormone agonists. Endocrinology 160(7), 1600–1612 (2019). https://doi.org/10.1210/en.2019-00111 CrossRefPubMed

10.

A.V. Schally, J.L. Varga, J.B. Engel, Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat. Clin. Pract. Endocrinol. Metab. 4(1), 33–43 (2008). https://doi.org/10.1038/ncpendmet0677 CrossRefPubMed

11.

H. Kiaris, I. Chatzistamou, A.G. Papavassiliou, A.V. Schally, Growth hormone-releasing hormone: not only a neurohormone. Trends Endocrinol. Metab. 22(8), 311–317 (2011). https://doi.org/10.1016/j.tem.2011.03.006 CrossRefPubMed

12.

G.C. Leonardi, G. Accardi, R. Monastero, F. Nicoletti, M. Libra, Ageing: from inflammation to cancer. Immun. Ageing 15, 1 (2018). https://doi.org/10.1186/s12979-017-0112-5 CrossRefPubMedPubMedCentral

13.

N. Ershaid, Y. Sharon, H. Doron, Y. Raz, O. Shani, N. Cohen, L. Monteran, L. Leider-Trejo, A. Ben-Shmuel, M. Yassin, M. Gerlic, A. Ben-Baruch, M. Pasmanik-Chor, R. Apte, N. Erez, NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis. Nat. Commun. 10(1), 4375 (2019). https://doi.org/10.1038/s41467-019-12370-8 CrossRefPubMedPubMedCentral

14.

P. Popovics, R. Cai, W. Sha, F.G. Rick, A.V. Schally, Growth hormone-releasing hormone antagonists reduce prostatic enlargement and inflammation in carrageenan-induced chronic prostatitis. Prostate 78(13), 970–980 (2018). https://doi.org/10.1002/pros.23655 CrossRefPubMed

15.

F.G. Rick, A.V. Schally, N.L. Block, M. Nadji, K. Szepeshazi, M. Zarandi, I. Vidaurre, R. Perez, G. Halmos, L. Szalontay, Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc. Natl Acad. Sci. USA 108(9), 3755–3760 (2011). https://doi.org/10.1073/pnas.1018086108 CrossRefPubMed

16.

M. Jaszberenyi, F.G. Rick, L. Szalontay, N.L. Block, M. Zarandi, R.Z. Cai, A.V. Schally, Beneficial effects of novel antagonists of GHRH in different models of Alzheimer’s disease. Aging 4(11), 755–767 (2012). https://doi.org/10.18632/aging.100504 CrossRefPubMedPubMedCentral

17.

M.A. Uddin, M.S. Akhter, S.S. Singh, K.T. Kubra, A.V. Schally, S. Jois, N. Barabutis, GHRH antagonists support lung endothelial barrier function. Tissue Barriers 7(4), 1669989 (2019). https://doi.org/10.1080/21688370.2019.1669989 CrossRefPubMed

18.

N. Barabutis, A. Siejka, A.V. Schally, Growth Hormone Releasing Hormone induces the expression of nitric oxide synthase. J. Cell Mol. Med. 15(5), 1148–1155 (2011). https://doi.org/10.1111/j.1582-4934.2010.01096.x CrossRefPubMed

19.

S.M. Waldherr, T.J. Strovas, T.A. Vadset, N.F. Liachko, B.C. Kraemer, Constitutive XBP-1s-mediated activation of the endoplasmic reticulum unfolded protein response protects against pathological tau. Nat. Commun. 10(1), 4443 (2019). https://doi.org/10.1038/s41467-019-12070-3 CrossRefPubMedPubMedCentral

20.

D.W. Cole, P.F. Svider, K.G. Shenouda, P.B. Lee, N.G. Yoo, T.M. McLeod, S.A. Mutchnick, G.H. Yoo, R.J. Kaufman, M.U. Callaghan, A.M. Fribley, Targeting the unfolded protein response in head and neck and oral cavity cancers. Exp. Cell Res. 382(1), 111386 (2019). https://doi.org/10.1016/j.yexcr.2019.04.007 CrossRefPubMedPubMedCentral

21.

A. Havighorst, Y. Zhang, E. Farmaki, V. Kaza, I. Chatzistamou, H. Kiaris, Differential regulation of the unfolded protein response in outbred deer mice and susceptibility to metabolic disease. Dis. Model Mech. 12(2) (2019). https://doi.org/10.1242/dmm.037242 CrossRef

22.

M. Livezey, J.E. Kim, D.J. Shapiro, A new role for estrogen receptor alpha in cell proliferation and cancer: activating the anticipatory unfolded protein response. Front. Endocrinol. 9, 325 (2018). https://doi.org/10.3389/fendo.2018.00325 CrossRef

23.

K.T. Kubra, M.A. Uddin, M.S. Akhter, N. Barabutis, Hsp90 inhibitors induce the unfolded protein response in bovine and mice lung cells. Cell Signal. 67, 109500 (2019). https://doi.org/10.1016/j.cellsig.2019.109500 CrossRefPubMed

24.

N. Barabutis, A.V. Schally, A. Siejka, P53, GHRH, inflammation and cancer. EBioMedicine 37, 557–562 (2018). https://doi.org/10.1016/j.ebiom.2018.10.034 CrossRefPubMedPubMedCentral

25.

A.X. Liu, D. Zhang, Y.M. Zhu, H.J. Gao, J.Y. Jiang, X.L. Hu, P.P. Lv, P.C. Leung, H.F. Huang, Impact of axis of GHRH and GHRH receptor on cell viability and apoptosis of the placental choriocarcinoma cell line. Curr. Mol. Med. 16(3), 299–311 (2016). https://doi.org/10.2174/1566524016666160225154040 CrossRefPubMed

26.

N. Barabutis, A.V. Schally, Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line. Proc. Natl Acad. Sci. USA 105(51), 20470–20475 (2008). https://doi.org/10.1073/pnas.0811209106 CrossRefPubMed

27.

M.S. Akhter, M.A. Uddin, N. Barabutis, Unfolded protein response regulates P53 expression in the pulmonary endothelium. J. Biochem. Mol. Toxicol. 33(10), e22380 (2019). https://doi.org/10.1002/jbt.22380 CrossRefPubMed

28.

S.Z.A. Shah, D. Zhao, T. Hussain, L. Yang, The role of unfolded protein response and mitogen-activated protein kinase signaling in neurodegenerative diseases with special focus on prion diseases. Front. Aging Neurosci. 9, 120 (2017). https://doi.org/10.3389/fnagi.2017.00120 CrossRefPubMedPubMedCentral

29.

H. Adhikari, N. Vadaie, J. Chow, L.M. Caccamise, C.A. Chavel, B. Li, A. Bowitch, C.J. Stefan, P.J. Cullen, Role of the unfolded protein response in regulating the mucin-dependent filamentous-growth mitogen-activated protein kinase pathway. Mol. Cell Biol. 35(8), 1414–1432 (2015). https://doi.org/10.1128/MCB.01501-14 CrossRefPubMedPubMedCentral

30.

N. Siwecka, W. Rozpedek, D. Pytel, A. Wawrzynkiewicz, A. Dziki, L. Dziki, J.A. Diehl, I. Majsterek, Dual role of endoplasmic reticulum stress-mediated unfolded protein response signaling pathway in carcinogenesis. Int. J. Mol. Sci. 20(18) (2019). https://doi.org/10.3390/ijms20184354 CrossRef

31.

A. Saito, K. Imaizumi, The broad spectrum of signaling pathways regulated by unfolded protein response in neuronal homeostasis. Neurochem. Int. 119, 26–34 (2018). https://doi.org/10.1016/j.neuint.2017.06.012 CrossRefPubMed

Titel: Growth hormone releasing hormone in the unfolded protein response context
verfasst von: Nektarios Barabutis
Publikationsdatum: 01.02.2020
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2020
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-020-02205-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

A severe inactivating PTH/PTHrP signaling disorder type 2 in a patient carrying a novel large deletion of the GNAS gene: a case report and review of the literature

Effects of low extracellular sodium on proliferation and invasive activity of cancer cells in vitro

Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients

Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans

High neutrophil-to-lymphocyte ratio is associated with relapse in Graves’ disease after antithyroid drug therapy